Baxter Announces Appointment of Interim President for Its Renal Business

Press Release

PDF

Deerfield, Ill -

Baxter International Inc. (NYSE:BAX) announced today that Jill Schaaf, who served as President, Renal, since May 2014, will be leaving the company. Effective May 3, 2016, Giuseppe Accogli, former region head for Baxter’s U.S. Renal business, has assumed the role of Interim President, Renal, while the company completes its search to permanently fill the role.

“We would like to express our gratitude to Jill for her 15 years of service to Baxter,” said Baxter Chairman and CEO José (Joe) Almeida. “Throughout her career at Baxter, Jill has been dedicated to improving the lives of our renal patients worldwide.”

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.